https://orcid.org/0000-0002-4737-2835
References
- Cenat, J., Farahi, S., Dalexis, R., Darius, W., Bekarkhanechi, F., Poisson, H., Broussard, C., Ukwu, G., Auguste, E., Nguyen, D. D., Sehabi, G., Furyk, S. E., Gedeon, A. P., Onesi, O., El Aouame, A. M., Khodabocus, S. N., Shah, M. S., & Labelle, P. R. (2022, October 15). The global evolution of mental health problems during the COVID-19 pandemic: A systematic review and meta-analysis of longitudinal studies. Journal of Affective Disorders, 315, 70–95. https://doi.org/10.1016/j.jad.2022.07.011
- Centers for Disease Control. (2022, March, 31). New CDC data illuminate youth mental health threats during the COVID-19 pandemic. CDC Newsroom Media Release. https://www.cdc.gov/healthyyouth/mental-health/index.html
- Daly, M., & Robinson, E. (2022, February 5). Depression and anxiety during COVID-19. The Lancet, 399(10324), 518. https://doi.org/10.1016/S0140-6736(22)00187-8
- Ettman, C., Cohen, G., Abdalla, S., Sampson, L., Trinquart, L., & Castrucci, B. (2022, January). Persistent depressive symptoms during COVID-19: A national, population-representative, longitudinal study of U.S. adults. Lancet, 5, 100091. https://doi.org/10.1016/j.lana.2021.100091
- Gilbert, D. (2022, December 30). This doctor prescribes ketamine to thousands online. It’s all legal. Washington Post.
- Harrington, A. (2020). Mind-fixers: Psychiatry’s troubled search for the biology of mental illness. W.W. Norton.
- Horowitz, M. A., & Moncrieff, J. (2021). Esketamine: Uncertain safety and efficacy data in depression. British Journal of Psychiatry, 219(5), 621–622. https://doi.org/10.1192/bjp.2021.163
- Kirsch, I. (2010). The emperor’s new drugs: Exploding the antidepressant myth. Basic Books.
- Lebowitz, M., Dolev-Amit, T., & Zilcha-Mano, S. (2021). Relationships of biomedical beliefs about depression to treatment-related expectancies in a treatment-seeking sample. Psychotherapy Theory, Research, Practice, Training, 58(3), 366–371. https://doi.org/10.1037/pst0000320
- Loughman, A., & Haslam, N. (2018). Neuroscientific explanations and the stigma of mental disorder: A meta-analytic study. Cognitive Research: Principles and Implications, 3(1), 43. https://doi.org/10.1186/s41235-018-0136-1
- Moncrieff, J. (2007). The myth of the chemical cure: A critique of psychiatric drug treatment. Palgrave Macmillan.
- Moncrieff, J., Cooper, R., Stockmann, T., Amendola, S., Hengartner, M., & Horowitz, M. (2022, July). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28(8), 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
- Peters, E. M., Halpape, K., Cheveldae, I., & Wanson, A. (2022). Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis. Experimental and Clinical Psychopharmacology, 31(3), 593–598. https://doi.org/10.1037/pha0000627
- Schroder, H., Duda, J., Christensen, K., Beard, C., & Björgvinsson, T. (2020, November). Stressors and chemical imbalances: Beliefs about the causes of depression in an acute psychiatric treatment sample. Journal of Affective Disorders, 276, 537–545. https://doi.org/10.1016/j.jad.2020.07.061
- Stone, M., Yaseen, Z., Miller, B., Richardville, K., Kalaria, S., & Kirsch, I. (2022). Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US food and drug administration individual participant analysis. The British Medical Journal, 378, e067606. https://doi.org/10.1136/bmj-2021-067606
- World Health Organization. (2017, January 3). Depression and other common mental disorders.
- Yapko, M. (1992). Hypnosis and the treatment of depressions: Strategies for change. Brunner/Mazel.
- Yapko, M. (Ed.). (2006). Hypnosis and treating depression: Applications in clinical practice. Routledge.
- Yapko, M. (2010). Hypnosis in the treatment of depression: An overdue approach for encouraging skillful mood management. International Journal of Clinical and Experimental Hypnosis, 58(2), 137–146. https://doi.org/10.1080/00207140903523137